UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Determine which funds deliver the best annual risk-adjusted returns and how they stack up. Compare contenders to pick winners.
28,456 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
When policymakers hint at rate moves, investors scramble to reprice risk. This guide breaks down how an evolving inte...
A veteran financial journalist breaks down abacus global (abx) 2025 Q4 results, explains what the numbers mean for 20...
SoundHound AI reports a 59% rise in Q4 revenue and a narrowed EBITDA loss, yet the stock has fallen year-to-date amid...
A leading U.S. health care powerhouse is quietly building an AI-driven engine that touches every corner of its busine...
As market yields shift, a growing cohort of investors turning $400,000 into passive income is using Delaware Statutor...
Schwab Fundamental International Equity ETF (FNDF) packs around 900 holdings into a single fund and has posted impres...
A top dividend-focused ETF is delivering gains, but I refuse to stop buying. Here’s how the approach stays discipline...
When a billionaire like David Tepper reportedly sold stakes in Nvidia and Amazon, it raises questions for regular inv...
The AI chip rally is shifting from training to real-world inference. This article explains why the next phase chip su...
In May, two Buffett-inspired bets stand out for patient investors. Learn why these favorite warren buffett stocks can...
Learn how to read nuwellis (nuwe) 2025 earnings and what the Q4 results may mean for investors. This guide breaks dow...